Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Nov 05, 2024

BUY
$17.75 - $41.6 $28,595 - $67,017
1,611 New
1,611 $63,000
Q1 2024

May 15, 2024

SELL
$17.75 - $41.6 $151,460 - $354,972
-8,533 Reduced 84.12%
1,611 $63,000
Q4 2023

Feb 14, 2024

BUY
$8.54 - $20.22 $32,631 - $77,260
3,821 Added 60.43%
10,144 $193,000
Q3 2023

Nov 14, 2023

BUY
$10.13 - $13.98 $37,288 - $51,460
3,681 Added 139.33%
6,323 $72,000
Q2 2023

Aug 14, 2023

BUY
$6.84 - $11.91 $8,994 - $15,661
1,315 Added 99.1%
2,642 $27,000
Q1 2023

May 15, 2023

SELL
$7.0 - $8.75 $12,796 - $15,995
-1,828 Reduced 57.94%
1,327 $10,000
Q4 2022

Feb 14, 2023

BUY
$5.45 - $7.35 $16,159 - $21,792
2,965 Added 1560.53%
3,155 $23,000
Q3 2022

Nov 14, 2022

BUY
$6.89 - $9.39 $702 - $957
102 Added 115.91%
190 $1,000
Q2 2022

Aug 15, 2022

SELL
$6.71 - $9.52 $4,193 - $5,950
-625 Reduced 87.66%
88 $1,000
Q1 2022

May 16, 2022

SELL
$6.41 - $13.89 $12,172 - $26,377
-1,899 Reduced 72.7%
713 $6,000
Q4 2021

Feb 14, 2022

BUY
$10.41 - $13.95 $14,875 - $19,934
1,429 Added 120.79%
2,612 $36,000
Q3 2021

Nov 15, 2021

BUY
$8.19 - $11.31 $3,177 - $4,388
388 Added 48.81%
1,183 $12,000
Q2 2021

Aug 16, 2021

BUY
$8.81 - $15.03 $7,003 - $11,948
795 New
795 $7,000

Others Institutions Holding ALPN

About ALPINE IMMUNE SCIENCES, INC.


  • Ticker ALPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,006,700
  • Description
  • Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...
More about ALPN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.